AML a Risk With PARP Inhibitors
Published: 2017-12-05 |
Author: Lisa A. Thompson, PharmD, BCOP |
Source: Oncology Nurse Advisor
Acute Myeloid Leukemia (AML) has been reported in patients receiving poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). Warnings about AML are listed in the prescribing information for the PARP inhibitors currently used in the United States.
AML has been reported in .05% to 2% of patients taking the various approved PARP inhibitors. Reports indicate that the patients had received prior treatment with platinum-based chemotherapy or other DNA-damaging agents, and most of the cases of AML were reported in patients with BRCA mutations. BRCA gene is involved with repair of DNA damage, and defects in DNA repair may increase the risk of developing AML. Because of this, AML is more of a concern in patients with BRCA mutations.
Regular monthly monitoring of complete blood counts (CBC) are recommended for patients taking PARP inhibitors. Patients with prolonged hematologic abnormalities should undergo further evaluation. If the patients develops AML, the PARP inhibitor should be discontinued.